Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Li Auto Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while Li Auto Inc trades at $12.31 (market cap $11.97B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.3× Li Auto Inc's market cap. Which is the better fit depends on your goals.
| ALNY | LI | |
|---|---|---|
Market Cap | $39.89B | $11.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $31.80 |
52-Week Low | $278.09 | $11.74 |
Enterprise Value | $38.15B | $888.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Li Auto (LI) trades at $12.10, down 1.6% with a bearish technical signal. Recent earnings show volatility with Q1 2026 missing estimates, while cash flow turned negative in 2025. The company faces intense competition and margin pressure, though analyst consensus remains cautiously optimistic with a $14.80 price target. Vehicle deliveries reached 30,895 in June 2026, indicating steady demand despite market headwinds.
Outlook hinges on execution of L series models and recovery from 2025-2026 trough years. Risks include aggressive discounting, regulatory challenges, and macroeconomic pressures in China's EV market. The stock presents a speculative opportunity if operational improvements materialize, but near-term volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
